Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1703 in EGPA
NCT05979051Phase 3Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2023
- Primary completion
- Dec 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-1703 in eosinophilic granulomatosis with polyangiitis (EGPA), sponsored by Hengrui Therapeutics. Started Nov 2023; status: recruiting.
02
Drugs
SHR-1703
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on NCT05979051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05979051.